EP4183389A1 — Pharmaceutical composition comprising apremilast
Assigned to KRKA dd · Expires 2023-05-24 · 3y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising apremilast, as well as to a process for the preparation thereof. Furthermore, the present invention pertains to a method for crystallizing apremilast, and to apremilast obtainable by this method. Furthermore…
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising apremilast, as well as to a process for the preparation thereof. Furthermore, the present invention pertains to a method for crystallizing apremilast, and to apremilast obtainable by this method. Furthermore, apremilast and pharmaceutical compositions for use as a medicament are disclosed.
Drugs covered by this patent
- Otezla (APREMILAST) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.